Generic Formulation Products

Finished Dosage Forms - Product List:

Download Brochure

Dr. Reddy’s Laboratories is a leading API supplier, with a presence in over 80 countries and a portfolio of 200+ ANDA filings and approved dossiers. Our offering goes beyond APIs and our global customers have access to high-quality dossiers and finished dosage forms.

Therapy Area

抗糖尿病

心臓血管

中枢神経系

胃腸疾患

その他

Anti-Obesity

Immuno Suppressant

腫瘍学

Oncology / Acromegaly

Dosage Form

オーラル

Injection

注射剤

Dossier Status

使用可能

Filed

開発中で

Therapy Area	Product Name	Strength	Dossier Status
その他	Ferric Carboxy Maltose	50 mg/ml	開発中で
その他	Thiamine	200 mg/2 ml 25's	Filed
その他	Naproxen Sodium	275 mg and 550 mg	Filed
その他	Posaconazole	100 mg	Filed
その他	Apremilast	10, 20 and 30 mg	Filed
その他	Amphotericin B	50 mg	開発中で
その他	Mesalamine	250 and 500 mg	開発中で
中枢神経系	Vigabatrin	USP 500 mg	Filed
中枢神経系	Dimethyl Fumarate	120 mg and 240 mg	開発中で
中枢神経系	Colchicine	0.6 mg	Filed
中枢神経系	Carboprost	USP Inj 250 mcg/ml PFS	Filed
中枢神経系	Topiramate ER	25, 50, 100 and 200 mg	Filed
中枢神経系	Edaravone	60 mg/100 ml	Filed
心臓血管	Tafamidis Meglumine	20 mg	開発中で
心臓血管	Bempedoic acid Ezetimibe	180 mg/10 mg	開発中で
心臓血管	Bempedoic acid	120 mg and 240 mg	開発中で
心臓血管	Edoxaban	15 mg, 30 mg and 60 mg	開発中で
心臓血管	Eltrombopag	12.5, 25, 50 and 75 mg	Filed
抗糖尿病	Sitagliptin HCL	25, 50, 100 mg	Filed
抗糖尿病	Sitagliptin Phosphate	25, 50 and 100 mg	Filed
抗糖尿病	Sitagliptin Phosphate + Metformin	50 + 500, 50 + 1000 mg	Filed
抗糖尿病	Sitagliptin HCL + Metformin	50 + 500, 50 + 850	開発中で
腫瘍学	Olaparib	100 mg and 150 mg	開発中で
腫瘍学	Liposomal Doxorubicin	2 mg/ml (10 ml and 25 ml)	Filed
腫瘍学	Pazopanib	200 and 400 mg	開発中で
腫瘍学	Fingolimod	0.5 mg	Filed
腫瘍学	Bortezomib	3.5 mg	Filed
腫瘍学	Bendamustine RTD	45 mg/ml (4 ml) and 25 mg/ml (4 ml)	Filed
腫瘍学	Cabazitaxel	40 mg/ml (1.5 ml)	Filed
腫瘍学	Carfilzomib	60 mg	Filed
腫瘍学	Busulfan	6 mg/ml (10 ml)	Filed

Therapy Area	Product Name	Dosage Form	EU Approval Status	US Approval Status
腫瘍学	Everolimus 2.5mg, 5mg & 10mg		Approved	NA
腫瘍学	Bortezomib For Injection 3.5 mg/vial	Injection	Approved	Approved

Products under patent(s) are offered only for R&D purposes U/S 107A of the Patent Act and not for commercial sale.

Product Capabilities

Research and Development	Manufacturing Facilities	Nich Product Opportunities	Vertical Integration
4 State-of-the-art R&D centres in India, U.K., U.S., and Netherlands 1200+ research scientists working on various projects	11 formulations manufacturing facilities	Peptides, Prostaglandins, HPAPIs, Innovative drug delivery, Novel dosage forms, Complex Injectables	More than 60% of our formulations are backward integrated with our In- house API

Our 11 formulations manufacturing facilities that are operated in accordance with cGMP (ICH Q7a) and regularly inspected/audited by international regulatory authorities and customers (USFDA, MHRA, EMA, PMDA, TGA, SAHPRA, ANVISA, Russian MoH, CFDA, COFEPRIS and Health Canada).

Dr. Reddy's has an expertise of developing and manufacturing various dosage forms:

Oral Solids	Injectables	Novel Dosage Forms
Tablets, Chewable tablets, Orodispersible	Lyophilized product and Liquid solution	Emulsions, Suspensions, Microspheres Liposomes tablets, Capsules, soft gel capsules Pellets a and Nanoparticles

Highly experienced and integrated technical team to support from filing-to-launch.
Highly experienced technical and global regulatory teams with experience of 350+ Filings and 150+ approvals across B2B markets.

Regulatory services	Tech Transfer support	Bio Study design support
Team of regulatory experts	Complete knowledge transfer	Clinical pharmacokinetic team available
Support filing activities	Support local manufacturing	Design bio study protocol
Across multiple countries of interest

Global Presence

Meet with our product experts in one-on-one virtual sessions

Our experts will answer your questions, provide advice, and help you understand our product better

Set Up a Meeting

免責事項

このウェブサイト上のいかなる情報も、製品またはサービスへの言及を含め、販売の申し出を構成するものではなく、販売の申し出を表すものと解釈されるものでもありません。有効な特許により保護されている製品は、商用目的で提供または提供されるものではありません。ただし、特定のケースでは、Dr. Reddy の独自の裁量により、現地の法的要件に従って、そのような製品の研究用数量が、規制免除が存在する場所に、インド特許法第 107A 条 (Bolar 免除) に基づく規制提出の目的で提供される場合があります。購入者は、それぞれの市場における特許シナリオを含む製品またはサービスについて独自の評価を行う必要があり、すべての特許関連法的責任を負うことになります。Dr. Reddy は、商品性、特定目的への適合性、および非侵害の保証を含むがこれらに限定されない、明示または黙示を問わずすべての保証を否認します。